Evaluation of State-Mandated Third Trimester Repeat HIV Testing in a Large Tertiary Care Center

Am J Perinatol
DOI: 10.1055/a-1925-2210

Third Trimester Repeat HIV Testing

Saba Berhie

1   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, United States (Ringgold ID: RIN12244)

2   Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, United States (Ringgold ID: RIN1861)

,

Stacy Tsai

3   Northwestern University Feinberg School of Medicine, Chicago, United States (Ringgold ID: RIN12244)

,

Emily S Miller

4   Obstetrics and Gynecology-Maternal Fetal Medicine, Northwestern University Feinberg School of Medicine, Chicago, United States

,

Patricia Garcia

5   Maternal Fetal Medicine, Northwestern University, Chicago, United States

,

Lynn M Yee

6   Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, United States

› Author Affiliations   SFX Search PDF Download Buy Article Permissions and Reprints

Objective: The Illinois Perinatal HIV Prevention Act was passed to ensure universal HIV testing once during pregnancy and was extended in 2018 to add third trimester repeat HIV screening. The objectives of this analysis were to describe uptake of, and patient factors associated with, third trimester repeat HIV testing at a high-volume birthing center. Study Design: This is a retrospective cohort study of people who delivered at a single tertiary care hospital in Illinois during 2018. Women who delivered before 27 weeks, had an intrauterine fetal demise, a known diagnosis of HIV, or no HIV test during pregnancy were excluded. Repeat testing was defined as an HIV test at or after 27 weeks’ gestation after an earlier negative HIV test during the same pregnancy. The primary outcome was the proportion of people who received repeat testing prior to delivery. Bivariable analyses were performed to identify patient characteristics associated with documentation of repeat HIV testing. Results: Of 12,053 people eligible for inclusion, 3.4% (N=414) presented without a documented third trimester repeat HIV test. The proportion of people with repeat testing improved from 80% to >99% in the first year. Patient factors were largely not associated with testing performance although multiparous people were more likely to have documented repeat testing. Conclusion: Rapid implementation of third trimester repeat HIV testing was achieved without disparity. Patient factors were largely not associated with testing performance, which reinforces the goal of a universal screen: to test all people equitably and effectively without bias.

Publication History

Received: 28 March 2022

Accepted after revision: 11 August 2022

Accepted Manuscript online:
16 August 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor , NY 10001 New York, USA

  

留言 (0)

沒有登入
gif